Open access
Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety
V. K. Rao
A. Šedivá
V. Dalm
A. Plebani
Catharina Schuetz
A. Shcherbina
A. Trizzino
Y. Zharankova
Alanvin Orpia
Elaine Kulm
J. Körholz
V. Lougaris
Y. Rodina
J. Bradt
A. Relan
G. Uzel
Medicine
Abstract
Leniolisib, a PI3Kδ inhibitor, improves the pathophysiology of APDS. This publication demonstrates the safety and efficacy of leniolisib in patients with APDS ≥12 years of age receiving up to 7 years of treatment, illustrating a positive tolerability profile and sustained disease burden reduction.